Haopeng Wang’s Post

Our team is thrilled to announce the publication of our latest study "Ligand-Induced Ubiquitination Unleashes LAG3 Immune Checkpoint Function" in 𝐂𝐞𝐥𝐥! This work unveils a molecular switch controlling LAG3 activation and paves the way for precision immunotherapy. 🔑 Key Findings: •  LAG3 undergoes rapid non-degradative polyubiquitination upon ligand engagement; • Ligand-induced ubiquitination activates LAG3 by releasing its tail from the membrane; •  LAG3 ubiquitination is required for its suppression of anti-tumor immunity in vivo; • LAG3/CBL co-expression identifies patients likely to respond to LAG3 blockade therapy. Huge thanks to our incredible collaboration with Chenqi Xu, Dario Vignali, Zhirong Shen and Dr. Yan Kong @ Peking University #CancerTreatment #CancerResearch #Immunotherapy #ScienceAdvances #LAG3